BioLargo, Inc. (BLGO) Stock Price & Analysis
BioLargo, Inc. (BLGO) closed at USD 0.07 on Thursday, October 15, 2026, down 12.50% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.08; the Oct 15, 2026 session ranged USD 0.07–0.08 on volume of 169,393 shares. Market capitalization is $23.01M, with a 52-week range of USD 0.07–0.2 (OQX). Source: Nexqual, retrieved October 16, 2026 at 07:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BLGO.md
Key facts (BLGO)
- Last four reported quarters (through Jun 30, 2026): revenue $4.1M, net income -$18.8M (-460.2% margin) (SEC filings).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (1 analysts), mean target USD 0.3 (range 0.3–0.3).
- Total return with dividends: 1Y -56.3% vs S&P 500 +18.1%; 5Y -61.1% vs S&P 500 +85.1%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BLGO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $2.5M | $5.9M | $12.2M | $17.8M | $7.8M | $4.1M |
| Gross profit | $1.1M | $2.9M | $6.2M | $7.9M | $3.4M | — |
| Operating income | -$6.8M | -$5.4M | -$4.6M | -$4.3M | -$14.9M | -$18.1M |
| Net income | -$6.9M | -$5.1M | -$4.6M | -$4.3M | -$15.2M | -$18.8M |
| EPS (diluted) | -$0.03 | — | — | — | — | — |
| Gross margin | 43.6% | 48.6% | 50.3% | 44.2% | 43.9% | — |
| Operating margin | -267.8% | -91.6% | -37.4% | -24.4% | -191.3% | -443.9% |
| Net margin | -272.4% | -87.2% | -38.0% | -24.5% | -195.6% | -460.2% |
| Revenue growth | +4.1% | +132.5% | +107.9% | +45.4% | -56.3% | — |
| Cash + short-term investments | $962K | $1.9M | $3.5M | $3.5M | $3.9M | — |
| Total debt | $494K | $337K | $355K | $1.1M | $2.1M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BLGO)
P/S 5.6x · Earnings yield -81.66%
Analysts (BLGO)
Consensus Buy (mean 2.00 on a 1–5 scale), 1 analysts; mean target USD 0.3 (low 0.3, high 0.3).
Total return (dividends reinvested) (BLGO)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -56.3% | -61.1% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -56.4% | -17.2% |
| Volatility (annualized) | 94.6% | 50.7% |
| Max drawdown | -65.0% (Jan 2026→Oct 2026) | -80.6% (Mar 2024→Oct 2026) |
Key Statistics (as of October 16, 2026 at 07:24 UTC)
| Price | USD 0.07 |
|---|---|
| Change | ▼ 12.50% (down) |
| Previous Close | USD 0.08 |
| Open | USD 0.08 |
| Day Range | USD 0.07 – 0.08 |
| 52-Week Range | USD 0.07 – 0.2 |
| Volume | 169,393 shares |
| Market Cap | $23.01M |
| Exchange | OQX |
Technical Analysis (BLGO)
Nexqual's technical model rates BLGO "SELL" based on 2 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 07:24 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.2 (oversold) |
| vs SMA50 | Below (USD 0.09) |
| MACD | -0.01 (negative) |
Analyst Ratings (BLGO)
Wall Street analysts rate BLGO "Buy" based on 1 analysts, with a mean price target of USD 0.3 (range USD 0.3–0.3), per Nexqual as of October 16, 2026 at 07:24 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 0.3 |
| High Target | USD 0.3 |
| Low Target | USD 0.3 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (BLGO)
| EPS Estimate | USD -0.01 |
|---|---|
| Revenue Estimate | $1.37M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.01 vs est -0.01 ▲ beat |
| 2026-03-31 | USD -0.01 vs est -0.01 ▲ beat |
| 2025-12-31 | USD -0.01 vs est -0.01 ▲ beat |
| 2025-09-30 | USD -0.01 vs est -0.01 ▲ beat |
Source: Nexqual, October 16, 2026 at 07:24 UTC.
Financials & Fundamentals (BLGO)
| Total Revenue | $4.08M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -55.10% |
| Gross Margin | +39.91% |
| Operating Margin | -298.72% |
| Profit Margin | +0.00% |
| ROE | -1128.59% |
| Current Ratio | 0.73 |
| Total Cash | $2.19M |
| Total Debt | $6.39M |
Source: Nexqual, October 16, 2026 at 07:24 UTC.
Financial Health Score (BLGO)
Nexqual rates BioLargo, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 07:24 UTC.
| Growth | Critical — Revenue -56% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $2M cash vs $6M debt |
| Cash Flow | Weak — Operating cash flow -$8M (FY ended Dec 2025, 10-K) |
| Efficiency | Critical — ROE -1129%, ROA -118.1% |
Ownership (BLGO)
| Insider Ownership | +14.19% |
|---|---|
| Institutional Ownership | +0.04% |
| Shares Outstanding | 328.73M |
| Float | 281.38M |
Source: Nexqual, October 16, 2026 at 07:24 UTC.
Leadership (BLGO)
BioLargo, Inc. is led by Dennis P. Calvert (age 62), Chairman, President & CEO, per Nexqual as of October 16, 2026 at 07:24 UTC.
| Chairman, President & CEO | Dennis P. Calvert (age 62) |
|---|---|
| Chief Financial Officer | Charles K. Dargan II, C.F.A. (age 69) |
| Executive VP of Operations, Corporate Secretary & Director | Joseph L. Provenzano (age 56) |
| Chief Science Officer & Director | Kenneth Reay Code (age 78) |
| President of Clyra Medical Technologies Inc | Steven V. Harrison (age 66) |
From BioLargo, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- BioLargo, Inc. invents, develops, and commercializes various platform technologies in the United States.
- The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances (PFAS) water contamination; advanced water and wastewater treatment; industrial odor and volatile organic compounds control, air quality control, and infection control; and myriad environmental remediation.
- It provides full-service environmental engineering, battery energy storage, and advanced antimicrobial medical device platforms.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLMT | Calumet, Inc | USD 58.24 | ▼ 0.6% |
| BCPC | Balchem Corporation | USD 170.53 | ▲ 0.48% |
| SXT | Sensient Technologies Corporati | USD 133.42 | ▲ 0.66% |
| AXTA | Axalta Coating Systems Ltd. | USD 33.73 | ▲ 0.6% |
| EMN | Eastman Chemical Company | USD 63.87 | ▲ 1.38% |
| WLK | Westlake Corporation | USD 63.61 | ▲ 2.83% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 07:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt